For example, enzalutamide may induce PD‐L1 expression in prostate cancer cells and in dendritic cells, supporting the concept that concurrent therapy with PD‐1 blockade and enzalutamide may have synergy.33 The ongoing phase 3 trial of enzalutamide with or without pembrolizumab (NCT03834493) will test the clinical benefits of this combination prospectively. Here, CD274 is linked to prostate carcinoma.